Close

237 epitope

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The 237 antibody is a model murine monoclonal scFv, it recognizes a mutated glycopeptide expressed by an aggressive murine fi brosarcoma tumor cell line called Ag104a. The tumor-specifi c glycopeptide is generated as a result of a mutated chaperone protein Cosmc that when repaired, ablates the 237 neo-epitope. Ag104A cells express both the OTS8 transmembrane protein and a mutated Cosmcchaperone, resulting in naturally high levels of expression of the 237 epitope.

  • CAR Vector Products

  • CAR Viral Particles

Loading...
  • Target Species:
  • Antibody Clone:
  • Antibody Host:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
CAR-MZ103 Anti-237 epitope (237) h(CD28-CD3ζ) CAR, pCDCAR1 Human 237 Mouse scFv-CD28-CD3ζ Retroviral T cell   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.